Skip to content

Adrienne C. Lahti

3 papers in the library · 444 citations · publishing 1995-2026

Papers

Sort Most recent Most cited

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara N Lappan, Richard C. Shelton et al. 4 citations

Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a...

Effects of ketamine in normal and schizophrenic volunteers.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology October 1, 2001 Adrienne C. Lahti, M A Weiler, B A Tamara Michaelidis et al.

This study evaluates the effects of ketamine on healthy and schizophrenic volunteers (SVs) in an effort to define the detailed behavioral effects of the drug in a psychosis model. We compared the effects of ketamine on normal and SVs to establish the comparability of their responses and the extent to which normal subjects might be used experimentally as a model. Eighteen normal volunteers (NVs)...

Ketamine activates psychosis and alters limbic blood flow in schizophrenia

Neuroreport April 1, 1995 Adrienne C. Lahti, Henry H. Holcomb, Deborah R. Medoff et al. 440 citations

The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a...